The information age has brought radical changes to scientific publishing. There are far more ways to get a piece of research out into the world, including non-peer-reviewed sources such as arXiv.org, fully open-access publications such as the PLOS family of journals, and open-access options from traditional journals such as the American Journal of Epidemiology (AJE). At the same time, the explosion of papers (and predatory journals (1-3)) has increased the need for curation of the vast amount of information available. Even filtered and democratized by searches on PubMed (http://www. ncbi.nlm.nih.gov) or Google Scholar (http://scholar.google. com, Google Inc., Mountain View, California), the volume of new papers is overwhelming (as anyone who receives tables of contents by email well knows). Thus, although in the past, journals wound up excluding work from the public sphere, they now often serve more to curate the vast flow of information, drawing the attention to the best work.
Journals themselves proliferate, though, and so it can be difficult to parse the good and reputable journals from those that are less good. The go-to metric for this purpose is the bibliographic impact factor (BIF), which has been much discussed (e.g., 4-12) in our sister journals of late, although not in depth in the pages of the AJE. In one of these commentaries, our own Editor-in-Chief remarked upon the "utter failure of the BIF as a marker of quality when comparing different journals" (5, p. 369). Seven years later, we do not appear much closer to solutions: Indeed, our publisher puts our BIF on the AJE homepage (http://aje.oxfordjournals.org).
The BIF was first mentioned by Eugene Garfield in 1955 (13) and by his own account first applied to journal rankings circa 1961 (14) . The BIF for the year 2014 for Journal X is calculated as the number of citations in 2014 of works published in Journal X in the years 2013 and 2012 divided by the number of "citable" articles (a poorly defined category (4)) published by Journal X over those same 2 years. The shortcomings of this measure are well-documented (4, (15) (16) (17) , many of which are particularly offensive to epidemiologists (4) . Another factor of special interest to readers of the AJE is the observation that it can take methodological innovations longer than 2 years to accumulate high citation counts (9), but such publications can have a long tail. In particular, methods papers are often cited regularly for a longer period of time than are (for example) substantive papers that might become outdated or that can (and indeed should!) be subsumed into meta-analyses and then are no longer directly cited but have a lasting indirect effect on knowledge.
I would like to note in passing the injustice by which one may publish an article that is a (or even the) key contributor to a highly cited meta-analysis only to have the article no be longer cited once the meta-analysis is written. A single trial or cohort study that contributes a plurality of the data (or of the information) to an influential meta-analysis is clearly influential and has "impact" in a broad sense. I propose that if a meta-analysis receives N citations and there are k contributing papers, each of which contributes some proportion P k of the information contained in the final point estimate, each paper should receive a citation bonus of N × P k × c, where c is a scaling factor between 0 and 1 (and initially placed at 0.5) that adjusts for the relative effort of the systematic review and meta-analysis itself.
An additional problem with BIF (another one to which epidemiologists should be highly sensitive) is that despite claims that it measures impact, the BIF does not account for the absolute number of high-impact papers published or the absolute number of citations (11) . If Journal X publishes exactly 1 citable paper in each of 2012 and 2013 (an interesting model for a journal, to be sure) and each paper is cited 100 times in 2014, then Journal X has a BIF of 200/2 = 100. Compare this to Journal Y, which publishes 100 citable papers in each of 2012 and 2013, each of which is cited 10 times in 2014. It would have a BIF of 2,000/200 = 10. Stipulating the strangeness of counting citations as a means of measuring impact, surely Journal Y (with 2,000 total citations) has had greater impact than did Journal X (with 200). However, the BIF suggests exactly the opposite.
Alternatives to the BIF exist (18, 19) . One more recent alternative metric, which has received relatively less attention within epidemiology, is the journal h-index. Invented by Hirsch (20) , the h-index for an individual is defined as the number of papers with citation number ≥ h (20) . If an investigator has 10 papers cited exactly 10 times each, she has an h-index of 10; her h remains 10 if she has 50 papers cited exactly 10 times each or 10 papers cited exactly 50 times each. If she has 10 papers cited exactly 8 times each, however, then her h-index is 8. Variations to account for authorship order have been proposed (21) .
Journal h-indices (see examples on Google Scholar (22)) are defined similarly, usually with a fixed window (2 or 5 years). Note that in the example above, the 2-year h-index for Journal X is precisely 2, whereas for Journal Y, that number is 10. The h-index is by no means perfect: Like the BIF, the h-index fails to distinguish the good citations from the bad, and the h-index of 2 for Journal X undersells the influence of the 2 published papers. However, the h-index has the advantage of rewarding not only depth of papers (how many citations of papers) but also breadth (how many useful papers were published). At the very least, it does not imply that Journal X with its 200 citations had a greater impact than Journal Y with its 2,000. Now seems the time to disclose that among relevant journals ranked by Google Scholar, the AJE has a 5-year h-index of 73 (22) and that the AJE does better in the rankings by h-index than by BIF (5-year BIF is reported on the journal homepage and is approximately 6). However, this is only relevant inasmuch as we discount the substantial problems of the h-index noted above. (It should also be noted that Google Scholar makes it relatively easy to see on which manuscripts and citations a journal's h-index is based.)
Is the h-index a more useful metric than the BIF? That depends: more useful for what purpose? The point is not to argue in favor of the h-index but rather to reiterate (4) one of the most fundamental lessons of epidemiology in the context of scientific journal rankings: namely, the methods used (in this case for ranking journals) should be foremost informed by the question we are asking. The close corollary of this lesson is that without a clear question, we cannot evaluate the adequacy of the methods, much less their results. The BIF is a measure that (flaws aside) seems to reward editorial specificity with respect to selection of articles that wind up being the most highly cited, as in the case of Journal X. We may instead wish for a metric that rewards not only highly cited papers but also publication of more highly cited (or simply more high quality) papers. The h-index might be an improvement over the BIF in this area, though it is far from perfect. If we simply wish to measure impact, then a simple citation count might be a better metric still.
What do we want a scientific journal-this Journal-to do? Ultimately, there is little disagreement with the idea that the AJE should publish work that in the end leads to the most improvement in public health-that we are all, ultimately, consequentialists (23, 24) . If we can agree on this point, then how do we think this end goal is best accomplished?
If we could estimate quality-adjusted life-years saved by articles published in a journal, we might argue in favor of that metric; however, this seems close to impossible, especially when considering methodological findings and innovations. Instead, should we seek to publish science that is both highquality and that we expect to be highly cited in the short term or simply high-quality science in general, regardless of our expectations of citations-with the confidence that such work will eventually find an audience? Are there are other axes entirely that we should think about optimizing?
The question remains open. The Editors of AJE invite your opinions on the subject.
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